Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$26.41 USD
+0.06 (0.23%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $26.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Akero Therapeutics, Inc. [AKRO]
Reports for Purchase
Showing records 21 - 40 ( 108 total )
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap; EFX Met Both Key NASH Endpoints in Phase 2b HARMONY Study; Cohort D Readout in 1H23; Raise PT to $64
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap: We Remain Highly Confident in a Positive Top-line Data Readout for Phase 2b HARMONY Next Month; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q Recap; Phase 2b HARMONY Top-Line Data Readout in 3Q22 Represents Major Milestone for Akero; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap; HARMONY Top-Line Results Remain on Target for 3Q22; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HARMONY Study Completes Enrollment; Top-line Data on Target in 3Q22; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Review; AASLD Data Show Impressive Evidence of Histologic Improvements Broadly at Just 16 Weeks
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Grants Fast Track Designation for EFX in the Treatment of NASH; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap: Two Phase 2b Trials Enrolling Patients With Both Fibrotic and Cirrhotic NASH; Affirm Buy, Modulate PT to $64
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Recap: HARMONY and SYMMETRY for Treating All Stages of NASH; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Raise Price Target to $68 on Clear Win for Early Data in Cirrhotic NASH; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 Recap: As Enrollment in HARMONY Continues, Cohort C Data Next Month a Key Catalyst
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Screening of Patients Underway for Phase 2b HARMONY Study of EFX; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Recap: Full Results of the Phase 2a BALANCED Study of EFX at AASLD; Raise PT to $64
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EFX First Drug to Receive PRIME Designation for the Treatment of NASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Final Program for Our Fourth Annual Virtual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BALANCED Trial Cohort C Fully Enrolled; First Cirrhotic NASH Data in 1H21; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Program for Our Fourth Annual Virtual NASH Investor Conference, October 5
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Plans for Adaptive Phase 2b/3 of EFX to Proceed with Written Guidance from the FDA; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E